Literature DB >> 2049228

Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

C J Doecke1, M E Veronese, S M Pond, J O Miners, D J Birkett, L N Sansom, M E McManus.   

Abstract

1. The metabolic interaction of phenytoin and tolbutamide in human liver microsomes was investigated. 2. Phenytoin 4-hydroxylation (mean Km 29.6 microM, n = 3) was competitively inhibited by tolbutamide (mean Ki 106.2 microM, n = 3) and tolbutamide methylhydroxylation (mean Km 85.6 microM, n = 3) was competitively inhibited by phenytoin (mean Ki 22.6 microM, n = 3). 3. A significant correlation was obtained between phenytoin and tolbutamide hydroxylations in microsomes from 18 human livers (rs = 0.82, P less than 0.001). 4. Sulphaphenazole was a potent inhibitor of both phenytoin and tolbutamide hydroxylations with IC50 values of 0.4 microM and 0.6 microM, respectively. 5. Mephenytoin was a poor inhibitor of both phenytoin and tolbutamide hydroxylations with IC50 values greater than 400 microM for both reactions. 6. Anti-rabbit P450IIC3 IgG inhibited both phenytoin and tolbutamide hydroxylations in human liver microsomes by 62 and 68%, respectively. 7. These in vitro studies are consistent with phenytoin 4-hydroxylation and tolbutamide methylhydroxylation being catalysed by the same cytochrome P450 isozyme(s) in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049228      PMCID: PMC1368377          DOI: 10.1111/j.1365-2125.1991.tb05499.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.

Authors:  H KUTT; M WOLK; R SCHERMAN; F MCDOWELL
Journal:  Neurology       Date:  1964-06       Impact factor: 9.910

2.  Sulphaphenazole and drug oxidation in man.

Authors:  D B Back; B K Park; J F Tjia; S N Newby
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

3.  Inheritance of phenytoin hypometabolism: a kinetic study of one family.

Authors:  M R Vasko; R D Bell; D D Daly; C E Pippenger
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

4.  Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

Authors:  S M Pond; D J Birkett; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  The effect of different sulfonamides on phenytoin metabolism in man.

Authors:  J M Hansen; J P Kampmann; K Siersbaek-Nielsen; I B Lumholtz; M Arrøe; U Abildgaard; L Skovsted
Journal:  Acta Med Scand Suppl       Date:  1979

6.  The metabolic fate of tolbutamide in man and in the rat.

Authors:  R C Thomas; G J Ikeda
Journal:  J Med Chem       Date:  1966-07       Impact factor: 7.446

7.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

8.  Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.

Authors:  R G Dickinson; W D Hooper; M Patterson; M J Eadie; B Maguire
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

9.  Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.

Authors:  J O Miners; L M Wing; D J Birkett
Journal:  Aust N Z J Med       Date:  1985-06

10.  Pharmacogenetics of tolbutamide metabolism in humans.

Authors:  J Scott; P L Poffenbarger
Journal:  Diabetes       Date:  1979-01       Impact factor: 9.461

View more
  26 in total

1.  The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation.

Authors:  Noritaka Ariyoshi; Katsuhiro Sho-no; Miki Nishimura; Michihiro Ito; Hiroyoshi Nakamura; Takayoshi Asai; Yasushi Saitoh; Takashi Ishizaki; Mitsukazu Kitada
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.

Authors:  P Bonnabry; T Leemann; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.

Authors:  M T Borin; S R Cox; B D Herman; B J Carel; R D Anderson; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 4.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

6.  Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.

Authors:  R Hyland; E G Roe; B C Jones; D A Smith
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 7.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

8.  Phenytoin-induced chronic hepatitis.

Authors:  A K Roy; H C Mahoney; R A Levine
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

9.  CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.

Authors:  Sean Hennessy; Charles E Leonard; Cristin P Freeman; Joshua P Metlay; Xin Chu; Brian L Strom; Warren B Bilker
Journal:  J Clin Pharmacol       Date:  2009-07-17       Impact factor: 3.126

10.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.